AstraZeneca Vaccination Senior Vaccination, Germany Ban vs EU Allow
Ministry of Food and Drug Safety to determine controversy over the effects of the elderly through 3-step verification
AstraZeneca vaccine, smooth supply and distribution advantages
AstraZeneca still controversy over the effects of the elderly… Inoculation interval is also variable
[앵커]
The government is starting expert verification from today (31) on the AstraZeneca vaccine, which has been controversial in its effectiveness in the elderly.
As soon as the next month, vulnerable groups such as the elderly will receive this vaccine, the verification results are paying attention.
This is Yeom Hye-won.
[기자]
AstraZeneca vaccine continues to be controversial for the prevention of the elderly.
Unlike Germany, where only those under the age of 65 have decided to vaccinate, the European Union has been paying attention to the Korean government’s decision as it approves that all age groups over 18 can be correct.
The Ministry of Food and Drug Safety is planning to verify external experts in three stages.
The first stage, the’Safety Effectiveness Verification Advisory Group’ meeting is held today.
It means that clinical experts focused on infectious medicine will participate to analyze clinical results and determine the appropriateness of vaccination targets.
The opinions of experts are divided.
It is a positive opinion that elderly people with low immunity are better to get vaccinations and reduce the chances of becoming severely ill, even if the effect is a little low.
[백순영 / 가톨릭대학교 의대 명예교수 : 효과가 95%냐, 80%냐 이런 것이 중요한 것이 아니라 일단 2회 접종을 제대로 잘 맞힐 수 있느냐, 이 1000만 명분의 관건이라고 할 수 있을 것이고 이 부분이 빨리 이루어진다 그러면 일단 우리가 백신에 의해서 면역력이 생기는 것뿐만 아니라…]
It is expected that the supply and demand will be smoother than other vaccines due to consignment production by domestic companies, and it is also an advantage that it does not require a cryogenic distribution system because it can be stored between 2 and 8 degrees.
However, it is hard to argue that a careful approach is necessary as the results are not highly reliable because only about 4% of the clinical subjects are in their 70s or older.
In addition, it is reported that the effectiveness of the vaccine varies depending on the interval between the first and second vaccinations, and some point out that close judgment is necessary.
[천은미 / 이대목동병원 호흡기내과 교수 : 8주 이내에 접종한 경우와 8주 이후에 접종한 경우 간격을 다르게 한 경우에 예방률이 다릅니다. 간격이라든지 용량에 대해서 정부가 어느 걸 선택을 해서 접종할 지가 저는 더 고심할 문제라고 생각합니다.]
The Ministry of Food and Drug Safety plans to synthesize these opinions and announce the results tomorrow (1st).
After that, a final review committee is held following the Central Pharmacist Review Committee to decide whether to approve the vaccine.
However, the government said that Kovacs, which decided to supply AstraZeneca and Pfizer vaccines, has not yet received specific notification regarding the quantity and timing of the vaccine.
YTN Yeom Hye-won[[email protected]]is.
※’Your report becomes news’ YTN awaits your valuable report.
[카카오톡] Search YTN to add a channel [전화] 02-398-8585 [메일] [email protected] [온라인 제보] www.ytn.co.kr
[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]
– .